Epizyme (EPZM) Tops Q2 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Epizyme Announces Second Quarter 2015 Financial Results and Provides Corporate Update
August 6, 2015 7:00 AM EDTInitiated 5-arm phase 2 study of tazemetostat in NHL Presenting updated data from solid tumor patients in the ongoing phase 1 study of tazemetostat at ESMOs European Cancer Congress in Vienna, Austria on September 26, 2015 As of June 30, 2015, Epizyme had cash and cash equivalents of $237 million, sufficient to fund planned operations through at least the end of the second quarter of 2017 Announced appointment of Rob Bazemore as President and Chief Executive Officer, effective September 10
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc.... More
